Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

39.10SEK
22 Feb 2018
Change (% chg)

-0.15kr (-0.38%)
Prev Close
39.25kr
Open
39.15kr
Day's High
39.25kr
Day's Low
38.05kr
Volume
88,745
Avg. Vol
89,011
52-wk High
84.25kr
52-wk Low
35.55kr

Chart for

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.15
Market Cap(Mil.): kr1,394.06
Shares Outstanding(Mil.): 19.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Medivir completes directed issue of around 155 mln SEK

* MEDIVIR HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY 155 MSEK

02 Feb 2018

BRIEF-Medivir Intends To Make A Directed Share Issue

* MEDIVIR - ‍MEDIVIR IS IN DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE III CTCL STUDY FOR REMETINOSTAT​

01 Feb 2018

BRIEF-Medivir: successful completion of pre-clinical safety studies with MIV-818

* SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

08 Jan 2018

BRIEF-Medivir announces new cancer project

* Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform

08 Nov 2017

BRIEF-Medivir Q3 EBITDA loss widens

* Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​

26 Oct 2017

BRIEF-Medivir receives FDA fast track designation for MIV-711 for treatment of OA

* Medivir receives FDA fast track designation for MIV-711 for the treatment of OA Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

24 Oct 2017

BRIEF-Medivir says positive top line data from 6-month initial phase IIa study of MIV-711

* Announces positive top line data from MIV-711-201, 6-month initial phase IIa study of MIV-711 in moderate knee osteoarthritis patients Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

11 Sep 2017

Earnings vs. Estimates